Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
51 hedge funds and large institutions have $573M invested in Prometheus Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
4% more funds holding
Funds holding: 49 → 51 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $585M → $573M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.01M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$3.48M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$2.52M |
| 4 |
State Street
Boston,
Massachusetts
|
+$979K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$363K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$3.43M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.63M |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$1.06M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$944K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$654K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $10K | -$14K | -593 | -59% |
|
|
52
Citadel Advisors
Miami,
Florida
| – | -$944K | -38,438 | Closed |
|
|
JF
53
Jump Financial
Chicago,
Illinois
| – | -$253K | -10,311 | Closed |
|
|
KCM
54
Kingdon Capital Management
New York
| – | -$204K | -8,317 | Closed |
|
|
PAM
55
Panagora Asset Management
Boston,
Massachusetts
| – | -$6K | -245 | Closed |
|
RXDX Hedge Fund Activity: Q3 2021 in Review
51 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q3 2021, worth a combined $573M — down 2.1% from $585M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RXDX positions and 4 closed out — a net gain of 2 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $4.01M. The largest seller was Suvretta Capital Management, cutting an estimated $3.43M.
- 51 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q3 2021, up from 49 in Q2 2021.
- Funds reported $573M of Prometheus Biosciences, Inc. Common Stock stock for Q3 2021, down 2.1% quarter-over-quarter.
- 6 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q3 2021 and 4 closed out, a net change of +2 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q3 2021 was Goldman Sachs, an estimated $4.01M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q3 2021 was Suvretta Capital Management, an estimated $3.43M sold.
Based on aggregated 13F filings for Q3 2021.